Metoprololtartrat Heumann (Metoprolol Tartrate)

Metoprolol tartrate selectively blocks β1‑adrenergic receptors in the heart, decreasing sympathetic stimulation. This leads to a slower heart rate, reduced contractility, and lower cardiac output, which together lower blood pressure and myocardial oxygen demand.

The specific dose of Metoprololtartrat is determined by the prescribing clinician based on the patient’s condition, response, and tolerability. Dosage adjustments are made according to clinical guidelines and individual therapeutic goals.

Safety data for metoprolol tartrate in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any potential risk to the fetus or infant, and decisions should be made in consultation with a healthcare professional.

To request Metoprololtartrat, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Metoprololtartrat is a cardioselective β1‑blocker, offering a lower risk of bronchospasm compared with non‑selective agents. Its pharmacokinetic profile provides once‑ or twice‑daily dosing options, making it convenient for many patients while maintaining effective blood pressure and heart‑rate control.

Metoprololtartrat should be stored at temperatures below 25 °C, in its original packaging, and protected from moisture and direct sunlight. Maintaining these conditions helps preserve the tablet’s stability and potency throughout its shelf life.

Metoprololtartrat is taken orally, usually with or without food, as directed by the prescriber. Tablets should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

Serious risks include severe bradycardia, marked hypotension, heart block, bronchospasm in patients with reactive airway disease, and worsening heart‑failure symptoms. Patients should be monitored for these events, especially during dose initiation or escalation.

Metoprololtartrat is contraindicated in patients with known hypersensitivity to metoprolol or other beta‑blockers, those with severe bradycardia, second‑ or third‑degree AV block without a pacemaker, and individuals in cardiogenic shock. Caution is also advised for patients with severe asthma or COPD.